It is important to give back to society all the scientific study that supported CoronaVac, says doctor in immunology
Publicado em:
01/01/1970
A milestone in terms of vaccine: this is how the scientific leader of Butantan, Denise Vilarinho Tambourgi, vice coordinator of the Centre of Excellence in New Target Discovery (CENTD), defines CoronaVac. The vaccine started the immunization process against Covid-19 in Brazil and is now administered in more than 40 countries on all continents. This is the result of dozens of national and international scientific studies that prove its effectiveness and safety.
Much of this research will be presented during the CoronaVac Symposium, an international event to be held by Butantan and Sinovac on the 7th, 8th and 9th of December, and which will promote discussions and debates between Brazilian researchers and specialists from countries such as the United States, Turkey, Chile, China and Spain.
“Since its development, much has been said about CoronaVac. I think it is important to return to society and peers all the scientific study that supported the formulation of the vaccine and that led to successful clinical trials, allowing the immunization of large groups of people in Brazil and abroad”, highlights Denise.
Nós usamos cookies e outras tecnologias semelhantes em nossos sites para melhorar o desenvolvimento de conteúdo interessante para nossos visitantes. Ao utilizar nossos sites, você concorda com tal monitoramento.
